Named Bioactive Compounds · Compound
Scopoletin (Coumarin)
Moderate Evidencecoumarin7 PubMed Studies
Hermetica Superfood Encyclopedia
Scopoletin is a coumarin compound found in various plants that demonstrates anti-angiogenic properties by inhibiting VEGFR2 and blocking endothelial cell proliferation. This bioactive compound also exhibits neuroprotective effects through acetylcholinesterase and monoamine oxidase inhibition in preclinical studies.
Scopoletin is a phenolic coumarin (6-methoxy-7-hydroxycoumarin) with molecular formula C₁₀H₈O₄, naturally occurring in numerous medicinal and edible plants. It is biosynthesized via ortho-hydroxylation of feruloyl-CoA or from 4-coumaroyl-CoA through hydroxylation involving cytochrome P450 enzymes, and extracted using solvents like ethanol or chloroform.
No human clinical trials, RCTs, or meta-analyses have been conducted on scopoletin supplementation. All available evidence is limited to preclinical in vitro and animal studies examining mechanisms like VEGFR2 autophosphorylation inhibition and effects on endothelial cells.
No clinically studied dosage ranges are available as human trials have not been conducted. Pharmacokinetic studies note low bioavailability and rapid absorption, but specific dosages or standardization levels have not been established. Consult a healthcare provider before starting any new supplement.
Scopoletin is a pure bioactive coumarin compound (7-hydroxy-6-methoxycoumarin), not a nutritional ingredient in the traditional macronutrient/micronutrient sense. Molecular weight: 192.17 g/mol. It contains no protein, fat, dietary fiber, or caloric value in physiologically relevant doses. As a secondary plant metabolite, it is present in various food sources at trace concentrations: found in Morinda citrifolia (Noni) fruit juice at approximately 0.025–1.0 mg per 100 mL depending on ripeness and processing; detected in Scopolia carniolica root at ~0.3–0.5% dry weight; present in tobacco leaves, sweet potatoes (Ipomoea batatas), and Artemisia species at sub-milligram per gram concentrations. Its primary identity is as a phenylpropanoid-derived hydroxycinnamic acid lactone. Bioactive concentration range in experimental studies: typically 10–100 µM in vitro; animal studies use 10–50 mg/kg doses. Bioavailability: lipophilic character (LogP ~1.4) suggests moderate passive intestinal absorption; undergoes hepatic Phase I (CYP450-mediated demethylation to esculetin) and Phase II glucuronidation/sulfation metabolism. Half-life estimated at 2–4 hours in rodent models. No established human dietary reference intake or RDA exists. Co-occurs with other coumarins (umbelliferone, esculetin) and iridoids in plant matrices, which may influence synergistic bioavailability.
Scopoletin exerts anti-angiogenic effects by specifically inhibiting vascular endothelial growth factor receptor 2 (VEGFR2), which prevents endothelial cell proliferation and new blood vessel formation. The compound demonstrates neuroprotective activity through dual inhibition of acetylcholinesterase and monoamine oxidase enzymes, potentially preserving neurotransmitter levels. Additionally, scopoletin shows antibacterial properties by targeting the FtsZ protein, which is essential for bacterial cell division.
Current research on scopoletin is limited to in vitro and preclinical studies, with no human clinical trials available. In vitro studies have demonstrated significant VEGFR2 inhibition and reduced endothelial cell proliferation, though specific IC50 values and concentration ranges vary across studies. Preclinical evidence shows acetylcholinesterase inhibition comparable to standard compounds, but effective dosages and bioavailability in humans remain unknown. The antibacterial effects have been observed in laboratory studies against various bacterial strains, but clinical applications have not been established.
Safety data for scopoletin supplementation in humans is extremely limited due to lack of clinical trials. As a coumarin derivative, scopoletin may theoretically interact with anticoagulant medications like warfarin, potentially affecting blood clotting mechanisms. The compound's monoamine oxidase inhibitory activity suggests possible interactions with antidepressants, particularly MAO inhibitors and SSRIs. Pregnancy and breastfeeding safety has not been established, and the compound should be avoided during these periods due to insufficient safety data.
